Vanguard Group Inc. increased its stake in Catalent Inc (NASDAQ:CTLT) by 15.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,881,737 shares of the company’s stock after buying an additional 1,039,117 shares during the period. Vanguard Group Inc. owned 6.32% of Catalent worth $181,201,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the company. Emerald Acquisition Ltd. acquired a new stake in Catalent during the second quarter worth $123,000. LS Investment Advisors LLC boosted its stake in Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock worth $164,000 after buying an additional 3,280 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in Catalent during the second quarter worth $204,000. Strs Ohio boosted its stake in Catalent by 17.7% in the second quarter. Strs Ohio now owns 9,300 shares of the company’s stock worth $213,000 after buying an additional 1,400 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Catalent during the second quarter worth $270,000.
Shares of Catalent Inc (NASDAQ:CTLT) opened at 24.00 on Wednesday. Catalent Inc has a 1-year low of $18.92 and a 1-year high of $32.24. The stock has a 50 day moving average price of $25.20 and a 200 day moving average price of $25.55. The firm has a market capitalization of $2.99 billion and a PE ratio of 26.97.
Catalent (NASDAQ:CTLT) last issued its quarterly earnings results on Monday, August 29th. The company reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by $0.01. The company earned $532.20 million during the quarter. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.61 earnings per share. Equities research analysts anticipate that Catalent Inc will post $1.40 earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on CTLT shares. Morgan Stanley reaffirmed a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. Jefferies Group reaffirmed a “hold” rating and set a $25.00 price target on shares of Catalent in a report on Tuesday, August 30th. TheStreet raised Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. Zacks Investment Research raised Catalent from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 5th. Finally, Wells Fargo & Co. raised Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Catalent has an average rating of “Hold” and a consensus price target of $28.67.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the company’s stock in a transaction on Friday, September 9th. The stock was sold at an average price of $23.58, for a total transaction of $403,234,623.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.